At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 23 enrolled
Drug / intervention
Tocilizumabdrug
Likely dose
Tocilizumab 8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating Tocilizumab for Rheumatoid Arthritis. Completed, enrolled 23 participants across 6 sites.
Detailed Summary
This open-label, single arm, multicenter long-term extension study of WA19926 (NCT01007435) will evaluate the safety and efficacy of tocilizumab in participants with early, moderate to severe RA who have completed the 104-week WA19926 (NCT01007435) core study. Eligible participants will be those who are expected to benefit from the study medicine based on the investigator's discretion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBrazil
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartDec 2013
Primary CompletionMay 2016
TodayJul 2026
First PostedAug 20, 2012
Enrollment StartDec 9, 2013
Primary CompletionMay 11, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 13.9 years ago
Interventions
Tocilizumabdrug
Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.